Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields ... Benzinga Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced the presentation of data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland being held November 7-10. The data showed that phosphatidylserine ... Data Presentation at Society for Immunotherapy of Cancer Annual Meeting ... |
